School-Based Malaria Screening and Treatment Reduces Plasmodium falciparum Infection and Anemia Prevalence in Two Transmission Settings in Malawi

J Infect Dis. 2022 Aug 12;226(1):138-146. doi: 10.1093/infdis/jiac097.

Abstract

Background: In areas highly endemic for malaria, Plasmodium falciparum infection prevalence peaks in school-age children, adversely affecting health and education. School-based intermittent preventive treatment reduces this burden but concerns about cost and widespread use of antimalarial drugs limit enthusiasm for this approach. School-based screening and treatment is an attractive alternative. In a prospective cohort study, we evaluated the impact of school-based screening and treatment on the prevalence of P. falciparum infection and anemia in 2 transmission settings.

Methods: We screened 704 students in 4 Malawian primary schools for P. falciparum infection using rapid diagnostic tests (RDTs), and treated students who tested positive with artemether-lumefantrine. We determined P. falciparum infection by microscopy and quantitative polymerase chain reaction (qPCR), and hemoglobin concentrations over 6 weeks in all students.

Results: Prevalence of infection by RDT screening was 37% (9%-64% among schools). An additional 9% of students had infections detected by qPCR. Following the intervention, significant reductions in infections were detected by microscopy (adjusted relative reduction [aRR], 48.8%; P < .0001) and qPCR (aRR, 24.5%; P < .0001), and in anemia prevalence (aRR, 30.8%; P = .003). Intervention impact was reduced by infections not detected by RDT and new infections following treatment.

Conclusions: School-based screening and treatment reduced P. falciparum infection and anemia. This approach could be enhanced by repeating screening, using more-sensitive screening tests, and providing longer-acting drugs.

Clinical trials registration: NCT04858087.

Keywords: adolescent; anemia; chemoprevention; intervention; schoolchildren.

Publication types

  • Clinical Study
  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Anemia* / diagnosis
  • Anemia* / epidemiology
  • Anemia* / prevention & control
  • Antimalarials* / therapeutic use
  • Artemether
  • Artemether, Lumefantrine Drug Combination / therapeutic use
  • Child
  • Humans
  • Malaria* / epidemiology
  • Malaria, Falciparum* / diagnosis
  • Malaria, Falciparum* / drug therapy
  • Malaria, Falciparum* / epidemiology
  • Malawi / epidemiology
  • Plasmodium falciparum
  • Prevalence
  • Prospective Studies
  • Schools

Substances

  • Antimalarials
  • Artemether, Lumefantrine Drug Combination
  • Artemether

Associated data

  • ClinicalTrials.gov/NCT04858087